Prospective Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2018; 24(13): 1478-1485
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1478
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
Masayoshi Yada, Masayuki Miyazaki, Kosuke Tanaka, Akihide Masumoto, Kenta Motomura
Masayoshi Yada, Masayuki Miyazaki, Kosuke Tanaka, Akihide Masumoto, Kenta Motomura, Department of Hepatology, Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan
Author contributions: Yada M and Motomura K wrote the paper; Yada M, Miyazaki M, Tanaka K, and Motomura K analyzed the data; Masumoto A supervised writing of the paper; all authors contributed to the manuscript.
Institutional review board statement: The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the Ethics Committee of Iizuka Hospital (Approve No. 26282).
Informed consent statement: Written informed consent was obtained from all patients.
Conflict-of-interest statement: The authors have no disclosures to report.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Masayoshi Yada, MD, PhD, Doctor, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. myadah1@aih-net.com
Telephone: +81-948-223800 Fax: +81-948-295744
Received: February 5, 2018
Peer-review started: February 5, 2018
First decision: February 26, 2018
Revised: February 26, 2018
Accepted: March 7, 2018
Article in press: March 7, 2018
Published online: April 7, 2018
Processing time: 58 Days and 8.4 Hours
Core Tip

Core tip: The real-world efficacy of sofosbuvir/ribavirin therapy for genotype 2 hepatitis C virus infection in Japan is high. Sofosbuvir/ribavirin therapy is safe and highly tolerated. History of hepatocellular carcinoma or interferon-based therapy independently reduces the efficacy of sofosbuvir/ribavirin therapy. Progressive liver fibrosis may attenuate the antiviral effect of sofosbuvir/ribavirin therapy.